LOBE:CC News and Press, Lobe Sciences Ltd. From 07/08/25

European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease. Covers Altemia(R) Medical Food Formula - The patented composition underpins Altemia(R), a physici...

New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™ $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addiction Option for an addition...

Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth. Mr. Yao brings over 25 years of experience across finance and biotech, with executive rol...

Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies US$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headache Lobe creates Cynaptec Pharmaceuticals, Inc...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) , a commercial stage biopharmaceutical company focused on developing products using lipid technology to treat diseases with significant unmet medica...